ADMA Biologics Inc. (ADMA)
Stock Price:
$3.03 USD
0.12 (4.12%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
Pre-market: $3.04 +0.01 (0.33%) Aug 14, 7:00 AM
Key Info
| Market Cap |
261.64M |
| Revenue (ttm) |
37.25M |
| Net Income (ttm) |
-61.42M |
| Shares Out |
86.35M |
| EPS (ttm) |
-0.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$3.03 |
| Previous Close |
$2.91 |
| Change ($) |
0.12 |
| Change (%) |
4.12% |
| Day's Open |
2.90 |
| Day's Range |
2.84 - 3.04 |
| Day's Volume |
3,192,584 |
| 52-Week Range |
1.45 - 5.48 |
More Stats
| Market Cap |
261.64M |
| Enterprise Value |
282.64M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
86.35M |
| Float |
67.93M |
| EPS (basic) |
-0.85 |
| EPS (diluted) |
-0.88 |
| FCF / Share |
-1.15 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.56M |
| Short Ratio |
1.86 |
| Short % of Float |
15.62% |
| Beta |
2.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.02 |
| PB Ratio |
3.21 |
| Revenue |
37.25M |
| Operating Income |
-50.77M |
| Net Income |
-61.42M |
| Free Cash Flow |
-99.02M |
| Net Cash |
-21.00M |
| Net Cash / Share |
-0.24 |
| Gross Margin |
-27.26% |
| Operating Margin |
-136.31% |
| Profit Margin |
-164.90% |
| FCF Margin |
-265.85% |
| ROA |
-18.96% |
| ROE |
-99.24% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.86*
(225.41% upside)
Low
6.00
Current: $3.03
High
15.00
Target: 9.86
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 29.35 | 16.99 | 22.76 | 10.66 | 7.18 | 5.92 | 3.07 | 1.12 | 0.76 |
| Revenue Growth | 72.79% | -25.37% | 113.49% | 48.53% | 21.34% | 92.84% | 174.35% | 46.92% | - |
| Gross Profit | -10.16 | -25.21 | -6.40 | 4.30 | 2.87 | 2.17 | 1.04 | 0.45 | 0.55 |
| Operating Income | -41.42 | -60.29 | -39.31 | -17.33 | -15.51 | -16.02 | -15.04 | -7.91 | -4.62 |
| Net Income | -48.28 | -65.74 | -43.76 | -19.52 | -17.97 | -16.81 | -15.53 | -7.30 | -5.90 |
| Shares Outstanding | 54.35 | 45.19 | 22.90 | 12.15 | 10.41 | 9.29 | 6.53 | 5.27 | 0.35 |
| Earnings Per Share | -0.89 | -1.45 | -1.91 | -1.61 | -1.73 | -1.81 | -2.38 | -1.39 | -16.72 |
| Operating Cash Flow | -76.19 | -62.68 | -37.27 | -18.27 | -15.42 | -14.70 | -10.89 | -6.90 | -1.43 |
| Capital Expenditures | -3.81 | -2.10 | -2.68 | -0.07 | -0.03 | -2.32 | -0.20 | -0.12 | - |
| Free Cash Flow | -80.01 | -64.77 | -39.95 | -18.34 | -15.44 | -17.03 | -11.08 | -7.02 | -1.43 |
| Cash & Equivalents | 26.75 | 26.75 | 48.61 | 15.31 | 16.84 | 21.88 | 29.10 | 13.00 | 0.44 |
| Total Debt | 83.43 | 44.10 | 42.97 | 20.22 | 15.69 | 14.77 | 5.08 | 3.97 | 0.55 |
| Net Cash / Debt | -56.68 | -17.35 | 5.64 | -4.92 | 1.14 | 7.11 | 24.02 | 9.03 | -0.11 |
| Assets | 127 | 88.88 | 108 | 23.69 | 23.71 | 27.02 | 31.98 | 15.56 | 2.93 |
| Liabilities | 101 | 69.11 | 67.69 | 28.14 | 22.89 | 21.01 | 10.41 | 6.13 | 2.54 |
| Book Value | 26.19 | 19.77 | 40.33 | -4.46 | 0.82 | 6.01 | 21.57 | 9.42 | 0.39 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ADMA Biologics Inc. |
| Country |
United States |
| Employees |
313 |
| CEO |
Adam S. Grossman |
Stock Information
| Ticker Symbol |
ADMA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ADMA |
Description
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.